Bausch Health announces results from analysis of adjudicated claims data

Bausch Health Companies announced findings from a retrospective database analysis of adjudicated claims data that examined the impact of access barriers for commercially-insured adults prescribed Xifaxan for reduction in risk of overt hepatic encephalopathy recurrence in adults. Results suggest potentially critical treatment gaps due to access barriers, which may result in increased rates of OHE-related hospitalizations. Findings from the analysis, “Assessment of Access Barriers to Rifaximin Among Patients with Overt Hepatic Encephalopathy Using Adjudicated Claims Data,” were presented today at the AMCP Nexus 2023 meeting. Treatment gaps were assessed across a 12-month period that began at the first observed attempt to access rifaximin, which is defined as a paid, reversed or rejected prescription claim. Across the study period, patients had 8.8 average attempts to access rifaximin with an average 6.4 claims paid, 1.5 rejected and 0.9 reversed Nearly all patients experienced a treatment gap of at least one day, with an average of 2.9 gaps per patient leading to a total duration of 157.4 days without exposure to rifaximin. Treatment-initiated delays in receiving rifaximin were experienced by 34.8% of patients with more than three-quarters of initiation delays experienced due to rejected claims with the most common rejection reported as Prior Authorization Required. Following initial paid claim, active treatment gaps were experienced by nearly three-quarters of patients with an average gap duration of 22.9 days. The retrospective database analysis used the IQVIA PharMetrics Plus database linked with Longitudinal Access and Adjudicated Data and identified 1,711 commercially insured adults with OHE who had at least one paid rifaximin prescription fill and 12-month continuous eligibility.